Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
143 studies found for:    Open Studies | "Thyroid Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting Study of Apatinib in Patients With Differentiated Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Drug: Apatinib
22 Recruiting I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer
Condition: Differentiated Thyroid Carcinoma
Interventions: Radiation: Radioiodine I-131;   Radiation: I-124
23 Recruiting Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study
Condition: Thyroid Cancer
Intervention: Drug: gemcitabine -oxaliplatine combination
24 Recruiting Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer Patients
Condition: Thyroid Cancer
Intervention: Radiation: 99mTc sestamibi
25 Recruiting Nintedanib(BIBF1120) in Thyroid Cancer
Conditions: Medullary Thyroid Cancer (MTC);   Differentiated Thyroid Cancer (DTC)
Interventions: Drug: Nintedanib;   Drug: Placebo
26 Recruiting A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Condition: Thyroid Cancer, Anaplastic
Intervention: Drug: Lenvatinib 24 mg
27 Recruiting Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
Condition: Thyroid Cancer
Intervention: Other: follow up visit
28 Not yet recruiting Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Condition: Differentiated Thyroid Cancer
Interventions: Drug: Donafenib 200mg;   Drug: Donafenib 300mg
29 Recruiting Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer
Condition: Non-Medullary Thyroid Cancer
Intervention:
30 Recruiting A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China
Condition: Differentiated Thyroid Cancer (DTC)
Interventions: Drug: Lenvatinib;   Drug: Placebo
31 Recruiting Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
Condition: Medullary Thyroid Cancer
Intervention: Other: 18F-DOPA
32 Not yet recruiting Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
Condition: Metastatic Thyroid Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Sirolimus
33 Recruiting Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
Condition: Differentiated Thyroid Cancer
Interventions: Drug: Anlotinib;   Drug: Placebo
34 Recruiting CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
Conditions: Thyroid Neoplasms;   Poorly Differentiated and Undifferentiated Thyroid Cancer;   Differentiated Thyroid Cancer
Intervention: Drug: CUDC-907
35 Recruiting Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Condition: Thyroid Carcinoma
Interventions: Drug: Continuous pazopanib (Arm A);   Drug: Intermittent pazopanib (Arm B)
36 Recruiting Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Condition: Thyroid Carcinoma
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
37 Recruiting interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Condition: Anaplastic Thyroid Cancer
Intervention: Other: Tissue, blood and clinical data collection
38 Recruiting Pioglitazone in Thyroid Cancers
Condition: Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
Intervention: Drug: Pioglitazone
39 Recruiting Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
Condition: Low Risk Differentiated Thyroid Cancer
Interventions: Drug: rhTSH stimulation;   Drug: I131;   Other: Follow up
40 Recruiting Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Condition: Anaplastic Thyroid Cancer
Intervention: Drug: Pembrolizumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.